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Immunology at 2000 Editorial
The last days of a year or century or millennium are the fine chemical specificity of the interactions could be
artificial barriers in time, but nonetheless to recognize understood. Much was learned from the identification
these points in time has some utility. They allow us to of different chemical forms of antigens and from the
pause, look back, and reappraise what we have done concepts of haptens and carriers. Haptens allowed for
and where we now are. As individual scientists, such the correct measurements of antibody affinity, which
reappraisals are perhaps not done with optimal fre- led to the recognition of affinity maturation during the
quency. As a group or a community, such reappraisals immune response. Biologically, we came to appraise
are uncommon and done even less to orient the field into the function of antibodies in opsonization, in activation
a forward direction. Scientific progress tends neither to of serum complement, and in immune complex±type
be organized nor well planned. It may pay little attention diseases and clinical allergies. The culmination of all
to the historically important events that moved a field these years was the elucidation of the beautiful structure
forward or to the natural forces that shaped the field, of an antibody molecule with its component chains and
but rather preys upon the immediate menu of findings, its unique functional domains.
new technologies, and fashionable lines of inquiry. We It is not that cellular reactions were completely ig-
now pause, albeit briefly, as year's end approaches and nored during this time. But progress here was slow and
our tenure as editors of Immunity terminates, to ponder the center of the field was elsewhere, i.e., with the analy-
what the second century of immunological research has sis of the ªhumoral response.º It is startling to realize
accomplished. Where are we? Where are we headed? that experimental proof that lymphocytes convey the
What are our expectations? specificity of immune responses has been known for
That day in July of 1798, when Edward Jenner inocu- about 30 years. Around late 1965, the second epoch of
lated James Phipps with vaccinia virus derived from a immunological research ended as the emphasis in the
cow named Blossom, represents the start of immunol- discipline abruptly changed with an increased aware-
ogy as a discipline. Following the extraordinary success ness of the phenomena reported by Ehrlich and Metch-
of cowpox vaccination in controlling smallpox, several nikoff, that is to say, the analysis of lymphocytes and
decades passed without any real understanding of im- the RES. From 1970, progress has been notable and
munological reactions. The analysis and understanding
revolutionary, as modern cellular and molecular biology
of these reactions arose from the formulation of the
and genetics enter this field, which has now exploded
germ theory of disease championed by Pasteur and
with extraordinary dynamism and has attracted someKoch, the discovery of neutralizing factors for toxins
of the best minds in biology. Now approaches could bein antiseraÐthe epochal results of Von Boehring and
taken to understand the cellular basis of an immuneKitasatoÐand our early comprehension of cells and tis-
response: the lymphocyte is the most studied and bestsues and diseases, brought about in particular by the
known cell in biology. The advances of the past twoemergence of the cell theory. The first century of immu-
decades in particular are nothing short of extraordinary,nology ended circa 1900 with the two giants who pro-
spilling beyond the confines of immunology per se. Fewfoundly influenced the analysis of immunological phe-
biological disciplines have had such an acute period ofnomena: Paul Ehrlich and Elie Metchnikoff. Ehrlich's
accomplishments. One can well argue that the disciplinerenowned Croonian lecture to the Royal Society in 1900,
moved so fast because we were firmly planted ªon theduring which he first stated the side chain theory, repre-
shoulders of giants.º Indeed, it had taken close to onesents creative thinking at its best. Remarkably, at this
century to get ready, but in barely three decades:time practically nothing was known of immunological
(1) Lymphocytes are defined as providing the cellularspecificity nor of the cells that conveyed it. Metchni-
basis for immunological specificity.koff's postulation on the role of phagocytes and phago-
(2) The two major subsets of lymphocytes are iden-cytosis was likewise a landmark in presaging what we
tified.now call innate immunityÐthe old reticulo-endothelial
(3) The clonal nature of lymphocyte recognition is de-system, actually not a bad term at all. These two extraor-
termined.dinary scientists defined how the immune system oper-
(4) The lymphocytes' receptors for antigen are discov-ated within the limits of their knowledge and created
ered and cloned.a vision of the future beyond the knowledge at their
(5) Monoclonal antibodies are developed, and withdisposal.
this accomplishment comes not only a fundamental un-But again, as with Jenner's findings, a period of time
derstanding of B cell biology, but also the widespreadhad to pass for their vision to come to the forefront of
use of homogeneous antibody finds enormous practicalimmunological research. Indeed, up to the late 1960s,
application.immunological research focused on the immediately ob-
(6) The molecular basis of diversity is resolved withvious and the technically feasible: the analysis of serum
the discovery of gene rearrangements.antibodies. We learned about the ways to elicit antibod-
(7) T cell recognition of antigen is deciphered, and theies and their role and use in combating infections. (The
MHC, discovered prior to this time, is now placed in thefirst Nobel Prize in Medicine was awarded to von Boehr-
correct perspective of physiological interactions.ing for his findings on serotherapy.) The different tech-
(8) Antigenicity is placed in the framework of antigennologies to appraise and measure the interactions be-
tween antigens and antibodies were developed so that processing, presentation, and peptide-binding to MHC,
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and the unique structure of MHC molecules is eluci- represented best by the lymphocyte; that is, we need
to define the interface between the worlds of Metchni-dated.
(9) The role of the thymus in T cell development and koff and Ehrlich. This interface has to be understood
not only at the usual reductionist level of identificationin the selection of T cells is discovered and with it comes
an understanding of immunological tolerance, discov- of the role of membrane proteins and cytokines, but in
the framework of the whole organism. We still need toered years earlier.
(10) A whole family of new molecules, the cytokines, know the many components involved in the reorganiza-
tion of lymphoid tissue as antigen enters them and whatare discoveredÐmost are purified and their genes
cloned. Cytokines are shown to orchestrate cellular may be the many controlling events taking place. We
have good readouts of positive and negative interac-communication, to promote and/or regulate most immu-
nological reactions, and to play key roles in promoting tions, but our sense is that there are very big gaps here
in our level of understanding. The same pertains to thehost defense and immunopathologic reactions.
(11) The mode of cell-to-cell communication is now end of the response.
Indeed, we need to define the transcriptional pro-examined at the fine molecular level as identification is
made of a whole set of membrane proteins that mediate grams that lead to the development of activated or dif-
ferentiated effector cells of the immune system. Thisdifferent expressions of cellular interactions; indeed, the
molecular mechanisms underlying intracellular signaling includes not only defining the tissue- and cell-specific
transcription factors that are involved in the process,within cells of the immune system starts to be under-
stood. but also in identifying the target genes of these transacti-
vating factors. Clearly, this is an area that has developed(12) The era of clinical immunology is launched: many
clinical diseases are identified to be caused by abnormal during the last years of this century and will be an ex-
tremely active area of research for many years to come.immunological reactions, and the molecular basis of
many of them is resolved; autoimmunities are acknowl- For this purpose we believe that genomics will play a
key role in driving immunologic research in the twenty-edged as important immunologically based diseases;
the relationship among microbes, their virulence, and first century, but not randomly. Rather, the future of
immunologic genomics rests in our ability to integratepathogenic components of the host begins to be under-
stood; and organ transplantation becomes a strong com- this technology into the biologic framework of our disci-
pline.ponent of modern medicine.
The third century of immunology research starts with Finally, we clearly need to bring more of the basic
principals we are learning about the immune systemthe decade of the 1970s, which was crucial, but, now
viewed in hindsight, mired with problems. Many good into the arena of human diseases. We still do not know
how to effectively tolerize to a particular antigen or toquestions were asked, but the time was not ripe to an-
swer all of them, and a few wrong roads were taken. allogeneic MHC±peptide complexes. Or, ironically, for
that matter, the principles of vaccination are far fromThis confusing decade nevertheless had to be endured
as the new cellular approaches were being created. Still, developed. We have made great strides in developing
immunologically based therapies against many of thevery notable findings came out of this period, such as
the realization that surface immunoglobulin was indeed great infectious diseases of our time. However, we are
still losing the battle against parasites, certain viruses,the B cell receptor for antigen and the landmark studies
on the role of the MHC and MHC restriction in T cell and intracellular bacteria, which have found ingenious
mechanisms to circumvent the immune response, oftenresponses, both of which poised the research, up to
this time. But by the 1980s, we were well on track, with by capturing a piece of the host defense system and
adapting it for its own use. This problem is particularlytechnology and biology finely integrated so that ques-
tions could now be asked that were never even thought relevant when applied to cancer. Although we now are
aware of a large number of proinflammatory and immu-of just 10±20 years before. It was at this time that
immunological phenomena began to be explained on a nomodulatory cytokines and their receptors, we are still
a long way off from using this knowledge therapeutically.mechanistic molecular basis. There was no longer a
split between ªcellularº and ªmolecularº immunologists. The challenge will be to identify specific patterns of
cytokines that drive a particular response and then findImmunology at the close of the century is on a path-
finding course from the outside of the cell into the nu- ways of eliciting or administering these cytokine arrays
to change the course of a human disease, particularlycleus. It has gone so fast that we have yet to stop and
integrate all the information brought about by gene autoimmune diseases such as arthritis, SLE, and IDDM.
Perhaps in the not-so-distant future it will be possibleknockouts, transgenics, the discovery of new genes,
and their manipulations. to circumvent the need for administering cytokines alto-
gether when the molecular pathways of cytokine signalSo what then are our predictions of what is to come?
Although this may indeed be a futile exercise that will transduction are fully worked out and the specific gene
targets of a particular cytokine can be turned on or offbe entirely negated by the next high impact papers, we
present here some of our thoughts. iatrogenically.
The four of us were fortunate to enter the field duringWe still need to know much more about how the im-
mune response starts and how it stops. The symbiosis the last period (albeit at different times!) and to partici-
pate in some of the events that have taken place. Janbetween the innate and the adaptive limbs of the im-
mune response remains a fertile area of research. Spe- Klein said, when admiring a painting by Gaugin and then
comparing a work of art to a work of a scientist, thatcifically, we need to determine how a nonclonal innate
system of recognition (i.e., the RES) operates and how we all contribute by placing chips in the vast mosaic of
science. Some of us may be fortunate to place a pieceit functions together with the clonal adaptive system
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that fits well and is prominent, while others may place
smaller pieces and, unfortunately, some may not fit well
and may even fall off. But the game was great fun to
play, since the mosaic has much beauty to it and to fill
in the pieces is always a challenge. Indeed, this is the
challenge to all of us, to recognize the vastness and the
beauty of the immunologic mosaic and to make sure
that all the chips, including the central ones, all fit well.
In a short while we will be ending our tenure as editors
of this journal. The journal was started because of the
vision of Benjamin Lewin that immunology was in a posi-
tion to have a major journal that would contain unique
and seminal papers. The Harvard editors who started
Immunity (Abul Abbas, Frederick Alt, Laurie Glimcher,
and Hidde Ploegh) made a superb effort in setting the
tone of Immunity, and indeed they deserve the major
credit for developing it. We followed through on the firm
base that was set up by them. We have many to thank
for the help that we were given. Benjamin Lewin was
always available to provide advice, and the staff at Cell
Press was always devoted to the journal and to making
sure that the authors were well served. So was our own
staff here at our Department of Pathology and the Center
for Immunology. The review editors, first Charles Jane-
way and later Alfred Singer, also provided much help.
The journal would not be a success were it not for the
help of our many colleagues who served as reviewersÐ
they have come from all over the world, and we thank
them all for their help. We received much help from our
colleagues at Washington University, who always went
out of their way to advise us on papers and to give this
advice in a very expeditious manner. But, of course, the
journal depends on the investigators who send us their
best work. We believe to have maintained the trust and
confidence of our fellow scientists everywhere. We have
tried to be fair, to base ourselves entirely on the merits
of the submitted paper, and to maintain a balance
among the areas that comprise immunobiology. Our
thanks to all and our best wishes to the third editorial
board.
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